Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Select Advanced Solid Tumors
Interventions: DRUG: IMC-F106C|DRUG: IMC-F106C and atezolizumab and pembrolizumab|DRUG: IMC-F106C and chemotherapy|DRUG: IMC-F106C and tebentafusp
Sponsor: Immunocore Ltd